Coral Laboratories Quarterly Results for Trading Insights
In 2026, Coral Laboratories (CORALAB) reported revenue ₹107 Cr and net profit ₹19 Cr. Check Coral Laboratories marketcap in USD to track the company's total market size over time.
CORALAB Quarterly Results — Revenue, Profit & EPS Highlights
Coral Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse CORALAB shareholder distribution to track promoter, FII and institutional holdings.
- Revenue of ₹86 Cr in March 2026 (+0.0% vs March 2026, -30.6% vs March 2025)
- Net Profit of ₹17 Cr in March 2026 (+0.0% vs March 2026, -29.2% vs March 2025)
- EBITDA of ₹15 Cr in March 2026 (+0.0% vs March 2026)
- Operating Margin of 18.0% in March 2026 (+0.0pp vs March 2026)
- Earnings Per Share of ₹45.85 in March 2026 (+0.0% vs March 2026)
Coral Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CORALAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | 2026 | March 2026 | March 2025 | March 2024 | March 2023 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 107 | 86 | 124 | 90 | 85 | 24.4% | - |
| Net Profit (₹ Cr) | 19 | 17 | 24 | 16 | 6 | - | - |
| EBITDA (₹ Cr) | 29 | 15 | 35 | 23 | 11 | - | - |
| EPS (₹) | 53.80 | 45.85 | 67.61 | 44.19 | 18.04 | - | - |
| Operating Margin (%) | 19.0% | 18.0% | 23.0% | 19.0% | 5.0% | - | - |
CORALAB Share Price Trend — 1-Year Movement Across Quarterly Results
Coral Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Coral Laboratories share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
CORALAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Coral Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1902.4 | 15,018 | 2,710 | -5.6% | - | 18.0% | 168.4 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8597.0 | 2,986 | 751 | -5.0% | - | 25.2% | 303.7 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4896.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 425.4 |
|
Cipla
Mar 2026 |
₹115,699.61 Cr | 1432.2 | 6,612 | 543 | -9.3% | - | 8.2% | 208.5 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1120.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.5 |
All amounts in ₹ Crores